1. INTERIM UPDATE FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA. (12th June 2019) Authors: Morschhauser, F.; Tilly, H.; Chaidos, A.; Phillips, T.; Ribrag, V.; Campbell, P.; Ghandi Laurent, D.; Jurczak, W.; McKay, P.; Opat, S.; Radford, J.; Rajarethinam, A.; Yang, J.; Howell, H.; Newberry, K.J.; Adib, D.; Salles, G. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 154 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗